Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis?

Classified as probably not a substantial claim.

In disease, microglial capacities can become either protective or damaging depending on context, timing, and molecular state.

“in disease, these same capacities can become either protective or damaging depending on context, timing, and molecular state [10,11,12].”

• cites [10] Merighi, S., Nigro, M., Travagli, A., and Gessi, S. (2022). Microglia and Alzheimer’s Disease. Int. J. Mol. Sci., 23. sourceSupported
• cites [11] Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., and Lan, J. (2023). Microglia in Alzheimer’s disease: Pathogenesis, mechanisms, and therapeutic potentials. Front. Aging Neurosci., 15. sourceSupported
• cites [12] Hansen, 2018, Microglia in Alzheimer’s disease, J. Cell Biol. sourceSupported

May combine two claims.

Microglia may help contain amyloid plaques, phagocytose pathological material, support synapses, and limit inflammatory spread; yet they may also release pro-inflammatory mediators, promote complement-associated synapse loss, propagate neurotoxic signaling, and contribute to chronic tissue damage.

“Microglia may help contain amyloid plaques, phagocytose pathological material, support synapses, and limit inflammatory spread; yet they may also release pro-inflammatory mediators, promote complement-associated synapse loss, propagate neurotoxic signaling, and contribute to chronic tissue damage.”

• cites [13] McFarland, 2022, Microglia in Alzheimer’s Disease: A Key Player in the Transition Between Homeostasis and Pathogenesis, Neurotherapeutics sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [19] Cai, Y., Liu, J., Wang, B., Sun, M., and Yang, H. (2022). Microglia in the Neuroinflammatory Pathogenesis of Alzheimer’s Disease and Related Therapeutic Targets. Front. Immunol., 13. sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

In homeostasis, microglia continuously survey the parenchyma, support neuronal integrity, contribute to synaptic remodeling, release trophic factors, and clear debris.

“Even in homeostasis, microglia continuously survey the parenchyma [6], support neuronal integrity [7], contribute to synaptic remodeling [8], release trophic factors [8], and clear debris [9]”

• cites [6] Nimmerjahn, 2005, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, Science sourceNot checked — no full text of the source
• cites [7] Guedes, 2022, Microglia-dependent remodeling of neuronal circuits, J. Neurochem. sourceSupported
• cites [8] Xie, 2026, Roles of Microglia in Synaptogenesis, Synaptic Pruning, and Synaptic Plasticity in Physiological Conditions and Central Nervous System Disorders, Curr. Neuropharmacol. sourceSupported
• cites [9] Rubio-Osornio, M., Rubio, C., Ganado, M., and Romo-Parra, H. (2026). The Double Face of Microglia in the Brain. Neuroglia, 7. sourceSupported

May combine two claims.

Microglial responses in Alzheimer's disease are not uniformly harmful and cannot be reduced to a simple activated-versus-resting distinction.

“more recent work suggests that microglial responses in Alzheimer’s disease are not uniformly harmful and cannot be reduced to a simple activated-versus-resting distinction [13,14].”

• cites [13] McFarland, 2022, Microglia in Alzheimer’s Disease: A Key Player in the Transition Between Homeostasis and Pathogenesis, Neurotherapeutics sourceSupported
• cites [14] Spangenberg, 2017, Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models, Brain Behav. Immun. sourceSupported

May combine two claims.

Alzheimer's plaques may induce not only inflammatory and phagocytic microglial responses, but also endogenous suppressive programs that limit tissue damage.

“Recent evidence suggests that PU.1-low CD28-positive microglia may restrain neuroinflammation and amyloid pathology, raising the possibility that Alzheimer’s plaques induce not only inflammatory and phagocytic microglial responses, but also endogenous suppressive programs that limit tissue damage.”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Postmortem human microglia include Alzheimer's-associated subsets, and microglial signatures differ across individuals, disease states, and technical platforms.

“Subsequent human studies extended this concept, showing that postmortem human microglia include Alzheimer ’s-associated subsets and that microglial signatures differ across individuals, disease states, and technical platforms [18].”

• cites [18] Olah, 2020, Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease, Nat. Commun. sourcePartly supported

  The Introduction and Discussion report human microglial subsets, including a cluster whose frequency is reduced in Alzheimer’s disease. The Results report inter-individual variation in cluster frequencies. They do not establish that signatures differ across technical platforms; the Results instead emphasize substantial similarity across experimental approaches, with some cluster-level differences. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Keren-Shaul et al. described disease-associated microglia as a distinct microglial type associated with neurodegenerative pathology, establishing that microglia can enter reproducible disease-linked transcriptional states.

“In 2017, Keren-Shaul et al. described disease-associated microglia as a distinct microglial type associated with neurodegenerative pathology, helping establish the idea that microglia can enter reproducible disease-linked transcriptional states [17].”

• cites [17] Spinrad, 2017, A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease, Cell sourceSupported

Probably not a substantial claim: may not pass S2 (checkable).

The older binary language of resting versus activated microglia is too limited.

“This older binary language is now considered too limited.”

• cites [5] Paolicelli, 2022, Microglia states and nomenclature: A field at its crossroads, Neuron sourceSupported
• cites [6] Nimmerjahn, 2005, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, Science sourceNot checked — no full text of the source
• cites [7] Guedes, 2022, Microglia-dependent remodeling of neuronal circuits, J. Neurochem. sourceSupported
• cites [8] Xie, 2026, Roles of Microglia in Synaptogenesis, Synaptic Pruning, and Synaptic Plasticity in Physiological Conditions and Central Nervous System Disorders, Curr. Neuropharmacol. sourceSupported
• cites [9] Rubio-Osornio, M., Rubio, C., Ganado, M., and Romo-Parra, H. (2026). The Double Face of Microglia in the Brain. Neuroglia, 7. sourcePartly supported

  Section 3, “Microglial Activation and Functional Polarization” (page unavailable), says microglial states form a context-dependent continuum that a binary model cannot capture. The paper identifies the older binary framework as M1 versus M2, however, rather than specifically resting versus activated microglia. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [10] Merighi, S., Nigro, M., Travagli, A., and Gessi, S. (2022). Microglia and Alzheimer’s Disease. Int. J. Mol. Sci., 23. sourceSupported
• cites [11] Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., and Lan, J. (2023). Microglia in Alzheimer’s disease: Pathogenesis, mechanisms, and therapeutic potentials. Front. Aging Neurosci., 15. sourcePartly supported

  Section 3 (Microglia activation; page unavailable) says the M1/M2 binary classification is contested and that intermediate phenotypes better reflect microglial activation states. This supports the broader point that binary language is too limited, but the paper does not specifically make that criticism of the resting-versus-activated distinction. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [12] Hansen, 2018, Microglia in Alzheimer’s disease, J. Cell Biol. sourceSupported

May combine two claims.

Alzheimer's neuroinflammation is a dynamic balance between protective and harmful microglial programs, with disease stage and local tissue environment determining whether immune activation is beneficial, insufficient, maladaptive, or toxic.

“Reviews and experimental studies now increasingly describe Alzheimer’s neuroinflammation as a dynamic balance between protective and harmful microglial programs, with disease stage and local tissue environment determining whether immune activation is beneficial, insufficient, maladaptive, or toxic [13,19].”

• cites [13] McFarland, 2022, Microglia in Alzheimer’s Disease: A Key Player in the Transition Between Homeostasis and Pathogenesis, Neurotherapeutics sourcePartly supported

  The Introduction describes early microglial activation as potentially protective and later chronic inflammation as potentially harmful; the section on preclinical models also describes context-dependent changes. But that section says whether specific microglial profiles relate to disease staging is unknown, so the claim that stage determines the outcome is stronger than the review supports. The four-way classification, particularly ‘insufficient’ activation, is not established in these passages. Page numbers were not available in our copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [19] Cai, Y., Liu, J., Wang, B., Sun, M., and Yang, H. (2022). Microglia in the Neuroinflammatory Pathogenesis of Alzheimer’s Disease and Related Therapeutic Targets. Front. Immunol., 13. sourceSupported

May combine two claims.

Microglial phagocytosis in Alzheimer's disease is not simply beneficial clearance; it can become misdirected toward vulnerable synapses, contributing directly to circuit failure.

“In this setting, microglial phagocytosis is not simply beneficial clearance; it can become misdirected toward vulnerable synapses, contributing directly to circuit failure.”

• cites [23] Hong, 2016, Complement and microglia mediate early synapse loss in Alzheimer mouse models, Science sourceSupported

May combine two claims.

Hong et al. showed that complement and microglia mediate early synapse loss in mouse models of Alzheimer's disease, with C1q and downstream complement signaling tagging synapses for removal before extensive plaque deposition.

“Hong et al. showed that complement and microglia mediate early synapse loss in mouse models of Alzheimer’s disease, with C1q and downstream complement signaling tagging synapses for removal before extensive plaque deposition [23].”

• cites [23] Hong, 2016, Complement and microglia mediate early synapse loss in Alzheimer mouse models, Science sourceSupported

May combine two claims.

DAM and MGnD are best understood not as inherently beneficial or harmful categories, but as context-dependent responses whose net effect depends on disease stage, brain region, and the balance between phagocytic containment and inflammatory injury.

“Thus, DAM and MGnD are best understood not as inherently beneficial or harmful categories, but as context-dependent responses whose net effect depends on disease stage, brain region, and the balance between phagocytic containment and inflammatory injury.”

• cites [16] Krasemann, 2017, The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases, Immunity sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [17] Spinrad, 2017, A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease, Cell sourcePartly supported

  The Discussion describes DAM as potentially beneficial in Alzheimer’s disease and proposes a trade-off between phagocytic activity and mechanisms that restrain immune activation. The Results also track DAM across disease stages. But the paper does not establish the claimed dependence on brain region or assess MGnD as a category, and it does not demonstrate that DAM’s net effect is determined by a balance between phagocytic containment and inflammatory injury. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Microglia are central regulators of Alzheimer's disease pathogenesis, and their roles cannot be reduced to a simple protective-versus-harmful dichotomy.

“Microglia are central regulators of Alzheimer’s disease pathogenesis, but their roles cannot be reduced to a simple protective-versus-harmful dichotomy.”

• cites [1] Abdulkhaliq, 2026, Amyloid-β and Tau in Alzheimer’s disease: Pathogenesis, mechanisms, and interplay, Cell Death Dis. sourcePartly supported

  The section “Microglia and GSK3β-mediated phosphorylation of tau” (page unavailable) describes microglia as governing CNS homeostasis and identifies a microglia-mediated mechanism that protects against tau pathology in Alzheimer’s disease. It does not establish that microglia are central regulators of Alzheimer’s pathogenesis or discuss why their roles cannot be reduced to a protective-versus-harmful dichotomy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [2] Wu, 2021, The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases, Transl. Neurodegener. sourcePartly supported

  The sections “Synaptic dysfunction in AD” and “Effects of microglia in tau-induced synaptic dysfunction” describe microglial contributions to synaptic maintenance as well as tau-associated synapse engulfment and dysfunction, supporting a more nuanced view than simply harmful or protective. The paper focuses on microglia’s role in tau-related synaptic dysfunction; it does not establish the broader claim that they are central regulators of Alzheimer’s disease pathogenesis. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [3] Hyman, 2014, The intersection of amyloid beta and tau at synapses in Alzheimer’s disease, Neuron sourcePartly supported

  The “Mechanisms of synaptic dysfunction and loss” section (page not provided) says activated microglia may contribute to synapse loss around plaques. It does not establish that microglia are central regulators of Alzheimer’s disease pathogenesis or discuss why their roles cannot be reduced to a protective-versus-harmful dichotomy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Ayata et al. reported that microglial contact with amyloid plaques can downregulate PU.1, and that lower PU.1 expression is linked to a lymphoid-like immunoregulatory program marked by receptors such as CD28.

“Ayata et al. reported that microglial contact with amyloid plaques can downregulate the transcription factor PU.1, and that lower PU.1 expression is linked to a lymphoid-like immunoregulatory program marked by receptors such as CD28.”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourceSupported

Classified as probably not a substantial claim. May combine two claims.

Ayata et al.'s study suggests that a small population of plaque-associated PU.1-low CD28-positive microglia may act as suppressive or neuroprotective microglia, reducing neuroinflammation and amyloid pathology in experimental models.

“Their study suggests that a small population of plaque-associated PU.1-low CD28-positive microglia may act as suppressive or neuroprotective microglia, reducing neuroinflammation and amyloid pathology in experimental models [20].”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourceSupported

May combine two claims.

Dejanovic et al. reported that C1q-dependent mechanisms can involve astrocytic synapse elimination and can compensate for altered microglial phagocytic function in an Alzheimer's model combining amyloid and tau pathologies.

“For example, Dejanovic et al. reported that C1q-dependent mechanisms can involve astrocytic synapse elimination and can compensate for altered microglial phagocytic function in an Alzheimer’s model combining amyloid and tau pathologies.”

• cites [24] Dejanovic, 2022, Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer’s disease mouse models, Nat. Aging sourcePartly supported

  The Main section reports C1q-dependent astrocytic synapse elimination in P301S mice. It separately reports that astrocytes partly compensate for impaired microglial phagocytosis in the amyloid-and-tau TauPS2APP model after Trem2 deletion; it does not establish that this compensation is C1q-dependent. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Sims et al. identified rare coding variants in TREM2, PLCG2, and ABI3 and argued that microglia-mediated innate immunity contributes directly to Alzheimer's disease biology, rather than merely representing a secondary inflammatory reaction to plaques and tangles.

“The study by Sims et al. identified rare coding variants in these genes and argued that microglia-mediated innate immunity contributes directly to Alzheimer’s disease biology, rather than merely representing a secondary inflammatory reaction to plaques and tangles [15].”

• cites [15] Sims, 2017, Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease, Nat. Genet. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Microglia in Alzheimer's disease should be understood as a spectrum of states shaped by plaque proximity, age, genetic background, metabolic stress, lipid handling, interferon signaling, complement activity, phagocytosis, and interactions with neurons and astrocytes.

“These studies made it clear that microglia in Alzheimer’s disease should be understood as a spectrum of states shaped by plaque proximity, age, genetic background, metabolic stress, lipid handling, interferon signaling, complement activity, phagocytosis, and interactions with neurons and astrocytes.”

• cites [18] Olah, 2020, Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease, Nat. Commun. sourcePartly supported

  The Introduction and Results (pages not provided) support diverse microglial states in the aging and AD brain, including subsets associated with AD pathology and an interferon-response-enriched cluster. But the paper does not establish the full list of factors shaping those states: it does not show roles for metabolic stress, lipid handling, complement activity, phagocytosis, or neuron–astrocyte interactions, and its Results found no association between cluster 7’s location and amyloid plaques. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

PU.1 and IRF8 are mutually reinforcing transcriptional regulators involved in microglial activation, and deletion of either factor impairs activation-related transcriptional programs.

“PU.1 and IRF8 have been described as mutually reinforcing transcriptional regulators involved in microglial activation, with deletion of either factor impairing activation-related transcriptional programs [34].”

• cites [34] Zhou, 2019, Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition, Protein Cell sourceSupported

May combine two claims.

Pimenova et al. examined Alzheimer's-associated PU.1 expression levels in microglial models and reported that higher SPI1 expression is associated with increased Alzheimer's risk, whereas lower expression is associated with protection.

“Pimenova et al. examined Alzheimer’s-associated PU.1 expression levels in microglial models and reported that higher SPI1 expression is associated with increased Alzheimer’s risk, whereas lower expression is associated with protection.”

• cites [31] Pimenova, 2021, Alzheimer’s-associated PU.1 expression levels regulate microglial inflammatory response, Neurobiol. Dis. sourceSupported

May combine two claims.

Podlesny-Drabiniok et al. linked MEF2C-regulated regulatory elements to candidate Alzheimer's disease risk genes and showed that, in a human triculture model containing Alzheimer's disease neurons and astrocytes, MEF2C-deficient microglia were associated with an increased DLAM population and a reduced Aβ42/40 ratio.

“Importantly, the authors linked MEF2C-regulated regulatory elements to candidate Alzheimer’s disease risk genes and showed that, in a human triculture model containing Alzheimer’s disease neurons and astrocytes, MEF2C-deficient microglia were associated with an increased DLAM population and a reduced Aβ42/40 ratio [25].”

• cites [25] Podlesny-Drabiniok, A., Kim, J.J., Bezemer, L.J., Patel, T., Cheng, H., Sewell, M., Montecillo, M., Church, N., Walley, A., and Garretti, F. (2026). MEF2C Controls Lysosomal and Lipid Clearance Programs Linked to Alzheimer’s Disease Risk in Macrophages. Res. Sq., preprint. sourceSupported

May combine two claims.

Alzheimer's disease risk can be influenced not only by coding changes in immune genes, but also by regulatory variants that alter how strongly a myeloid transcription factor is expressed.

“The key implication was that Alzheimer’s risk could be influenced not only by coding changes in immune genes, but also by regulatory variants that alter how strongly a myeloid transcription factor is expressed.”

• cites [12] Hansen, 2018, Microglia in Alzheimer’s disease, J. Cell Biol. sourceSupported
• cites [29] Huang, 2017, A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease, Nat. Neurosci. sourceSupported

May combine two claims.

Studies of Spi1 dosage in mice suggest that modest changes can reshape the microglial transcriptome, but the biological consequences depend on timing, magnitude, and disease context.

“Similarly, studies of Spi1 dosage in mice suggest that modest changes can reshape the microglial transcriptome, but the biological consequences depend on timing, magnitude, and disease context [33].”

• cites [33] Jones, 2021, Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease, Sci. Rep. sourcePartly supported

  The Results and Discussion (pages unavailable) show that modest Spi1 changes altered the transcriptome of mouse microglia in primary mixed-glial cultures, with different pathways affected by reduced and increased dosage. The Discussion cautions that these cultures do not fully replicate the in vivo context. The paper does not establish that biological consequences depend on timing or disease context, or demonstrate the transcriptomic effects in mice in vivo. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S2 (checkable).

A lymphoid-like suppressive microglial state would add a missing layer to the current taxonomy: not simply homeostatic, inflammatory, or plaque-clearing microglia, but microglia that may regulate the intensity and consequences of neuroimmune activation.

“A lymphoid-like suppressive microglial state would therefore add a missing layer to the current taxonomy: not simply homeostatic microglia, inflammatory microglia, or plaque-clearing microglia, but microglia that may regulate the intensity and consequences of neuroimmune activation.”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourceSupported

May combine two claims.

CD4-positive T cells in preclinical Alzheimer's disease show a type 2 helper profile and reactivity against Aβ-derived peptides, whereas MCI subjects show increased pro-inflammatory CD8-positive effector/TEMRA cells.

“Recent human work combining CyTOF, single-cell RNA sequencing, T-cell secretome analysis, and antigen-presentation assays reported that CD4-positive T cells in preclinical Alzheimer’s disease show a type 2 helper profile and reactivity against Aβ-derived peptides, whereas MCI subjects show increased pro-inflammatory CD8-positive effector/TEMRA cells.”

• cites [37] Rickenbach, 2025, Altered T-cell reactivity in the early stages of Alzheimer’s disease, Brain sourceSupported
• cites [39] Ohyagi, 2025, Stage-specific roles of clonally expanded CD8+ T cells in regulating amyloid pathology in Alzheimer’s disease models, Nat. Commun. sourceCould not verify

  The Results describe effector CD8+ T cells in Alzheimer’s mouse models, not the claimed comparison between people with preclinical Alzheimer’s disease and those with MCI. Searches for CD4+ type 2 helper cells, Aβ-peptide reactivity, MCI/TEMRA cells, and the stated combination of human-study methods found no passage reporting those findings. The Results’ unsuccessful Aβ42 stimulation assay concerns mouse CD8+ T-cell receptors and does not resolve the claim about human CD4+ cells. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

Lowering PU.1 may reduce risk-associated or inflammatory programs, but too much suppression could compromise microglial survival, plaque engagement, phagocytosis, or other protective functions.

“This creates a central tension for Alzheimer’s therapeutics: lowering PU.1 may reduce risk-associated or inflammatory programs, but too much suppression could compromise microglial survival, plaque engagement, phagocytosis, or other protective functions.”

• cites [32] Smith, 2013, The transcription factor PU.1 is critical for viability and function of human brain microglia, Glia sourceNot checked — no full text of the source
• cites [33] Jones, 2021, Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease, Sci. Rep. sourcePartly supported

  The Discussion (page unavailable) suggests that reduced PU.1 may produce a less reactive microglial phenotype and reports evidence that diminished PU.1 can increase vulnerability to cell death. The Introduction (page unavailable) reports reduced phagocytic capacity after PU.1 reduction. These passages support the proposed tension, but the paper does not establish that PU.1 suppression compromises plaque engagement or define a level of suppression at which protective functions are lost. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

PU.1 is required for microglial identity and viability, and excessive reduction may impair essential functions.

“Because PU.1 is required for microglial identity and viability, excessive reduction may impair essential functions.”

• cites [32] Smith, 2013, The transcription factor PU.1 is critical for viability and function of human brain microglia, Glia sourceNot checked — no full text of the source
• cites [33] Jones, 2021, Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease, Sci. Rep. sourcePartly supported

  The Introduction (page unavailable) reports that reduced PU.1 changes microglial gene expression and reduces phagocytic capacity, supporting the concern about impaired function. It discusses PU.1 in lineage determination but does not establish that it is required for microglial identity. The Discussion (page unavailable) reports that viability appeared unaffected after PU.1 reduction in the cited microglial experiments, so the claim that PU.1 is required for microglial viability is not supported. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

Constitutive or postnatal Irf8 deletion caused a loss of microglial identity genes and a gain of disease-associated microglia-like and interferon-related genes, indicating that disruption of one core transcription factor can redirect microglia toward disease-like states.

“Constitutive or postnatal Irf8 deletion caused a loss of microglial identity genes and a gain of disease-associated microglia-like and interferon-related genes, indicating that disruption of one core transcription factor can redirect microglia toward disease-like states [28].”

• cites [28] Saeki, 2024, IRF8 defines the epigenetic landscape in postnatal microglia, thereby directing their transcriptome programs, Nat. Immunol. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

PU.1 belongs to the ETS family of transcription factors and is central to myeloid lineage specification, including the development and functional identity of macrophages and microglia.

“PU.1 belongs to the ETS family of transcription factors and is central to myeloid lineage specification, including the development and functional identity of macrophages and microglia.”

• cites [26] Saeki, 2025, Transcription factors that define the epigenome structures and transcriptomes in microglia, Exp. Hematol. sourcePartly supported

  The PU.1 section identifies PU.1 as an Ets-family transcription factor and describes its role in hematopoietic cell fate and microglial identity. “A stepwise development of microglia” also says microglial progenitors emerge through PU.1-dependent pathways. Our copy does not establish the same developmental and functional-identity role for macrophages generally. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [27] Yeh, 2019, Transcriptional and Epigenetic Regulation of Microglia in Health and Disease, Trends Mol. Med. sourcePartly supported

  The ‘Elucidating critical transcriptional regulators’ section identifies PU.1 as an ETS-domain transcription factor involved in immune-cell and microglial development. ‘The role of PU.1 in the maintenance of homeostatic microglia’ calls it a master regulator of microglial development and function. The copy does not establish the claim about macrophage development and functional identity specifically; page numbers were not available. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

A common protective haplotype associated with lower SPI1 expression was reported to delay Alzheimer's disease onset, suggesting that reduced PU.1 abundance in myeloid cells may be beneficial under some disease-relevant conditions.

“A common protective haplotype associated with lower SPI1 expression was reported to delay Alzheimer’s disease onset, suggesting that reduced PU.1 abundance in myeloid cells may be beneficial under some disease-relevant conditions.”

• cites [12] Hansen, 2018, Microglia in Alzheimer’s disease, J. Cell Biol. sourceSupported
• cites [29] Huang, 2017, A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease, Nat. Neurosci. sourceSupported

May combine two claims.

In the 5xFAD model, Irf8 deletion reduced microglial interaction with amyloid plaques and was associated with reduced plaque size and less neuronal loss.

“In the 5xFAD model, Irf8 deletion also reduced microglial interaction with amyloid plaques and was associated with reduced plaque size and less neuronal loss.”

• cites [28] Saeki, 2024, IRF8 defines the epigenetic landscape in postnatal microglia, thereby directing their transcriptome programs, Nat. Immunol. sourceSupported

May combine two claims.

Lowering PU.1 expression in microglia reduced amyloid disease severity in mice and was linked to expression of immunoregulatory lymphoid receptor proteins, particularly CD28.

“Their study reported that lowering PU.1 expression in microglia reduced amyloid disease severity in mice and was linked to expression of immunoregulatory lymphoid receptor proteins, particularly CD28.”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourceSupported

May combine two claims.

Microglia in Alzheimer's disease appear to acquire hybrid programs: they remain tissue-resident myeloid cells but can express genes normally associated with professional antigen presentation, immune communication, and inflammatory coordination.

“Instead, microglia in Alzheimer’s disease appear to acquire hybrid programs: they remain tissue-resident myeloid cells, but they can express genes normally associated with professional antigen presentation, immune communication, and inflammatory coordination.”

• cites [18] Olah, 2020, Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease, Nat. Commun. sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [46] Chen, 2021, Microglia in Alzheimer’s disease at single-cell level. Are there common patterns in humans and mice?, J. Exp. Med. sourceSupported
• cites [47] Leal, 2025, The Human Microglia Atlas (HuMicA) unravels changes in disease-associated microglia subsets across neurodegenerative conditions, Nat. Commun. sourceSupported

May combine two claims.

Many disease-associated microglial programs are spatially enriched around plaques, suggesting microglial state transitions are disease-stage-dependent and anatomically localized.

“Many disease-associated microglial programs are spatially enriched around plaques, which suggests that microglial state transitions are not only disease-stage-dependent but also anatomically localized.”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourcePartly supported

  The Main section (page unavailable) reports that PU.1-low disease-associated microglia preferentially co-localize with amyloid plaques in 5xFAD mice and people with Alzheimer’s disease, and increase in number with disease progression. It also describes plaque-associated cues driving PU.1 downregulation. These findings support anatomical localization and a progression-related change for this subpopulation, but do not establish that many microglial programs are plaque-enriched or that microglial state transitions generally depend on disease stage. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [46] Chen, 2021, Microglia in Alzheimer’s disease at single-cell level. Are there common patterns in humans and mice?, J. Exp. Med. sourcePartly supported

  The 'Innovative approaches for investigating human microglia in AD' section (page unavailable) reports a spatial association between DAM and amyloid plaques, and 'Proliferating microglia' reports Ki67-positive microglia around plaques in 5xFAD mice. The paper also describes changes in microglial states with disease progression, but it does not establish that many distinct microglial programs are spatially enriched around plaques. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [47] Leal, 2025, The Human Microglia Atlas (HuMicA) unravels changes in disease-associated microglia subsets across neurodegenerative conditions, Nat. Commun. sourcePartly supported

  The Results section (‘Pathology-associated alterations in microglia subpopulations’; page unavailable) describes qualitative colocalization of GPNMB-high microglia with potential amyloid plaques in Alzheimer’s disease samples. It does not establish that many disease-associated programs are enriched around plaques or that microglial state transitions depend on disease stage. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

In inflammatory and neurodegenerative settings, microglia can upregulate antigen-presentation machinery, respond to interferon-γ and other lymphocyte-derived cytokines, and influence T-cell behavior within or near the central nervous system.

“In inflammatory and neurodegenerative settings, microglia can upregulate antigen-presentation machinery, respond to interferon-γ and other lymphocyte-derived cytokines, and influence T-cell behavior within or near the central nervous system.”

• cites [44] Das, 2019, Microglial priming of antigen presentation and adaptive stimulation in Alzheimer’s disease, Cell Mol. Life Sci. sourceNot checked — no full text of the source
• cites [45] Almolda, 2015, Are Microglial Cells the Regulators of Lymphocyte Responses in the CNS?, Front. Cell Neurosci. sourceSupported

May combine two claims.

The clinical translation of broad anti-inflammatory approaches has been disappointing, partly because inflammation in Alzheimer's disease is not a single harmful process that can simply be turned off.

“However, the clinical translation of broad anti-inflammatory approaches has been disappointing, partly because inflammation in Alzheimer’s disease is not a single harmful process that can simply be turned off [48,49].”

• cites [48] McGeer, 2007, NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies, Neurobiol. Aging sourceNot checked — no full text of the source
• cites [49] Krause, 2010, Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer’s disease, Int. J. Alzheimers Dis. sourceSupported

May combine two claims.

The PU.1-low CD28-positive population is a small plaque-associated subset, not a bulk transformation of all microglia.

“The PU.1-low CD28-positive population appears to fit this spatial logic: it is not described as a bulk transformation of all microglia, but as a small plaque-associated subset.”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourceSupported

May combine two claims.

Microglia-specific CD28 deficiency promoted a broader inflammatory microglial state together with increased amyloid plaque burden.

“CD28 was expressed by a small subset of plaque-associated PU.1-low microglia, and microglia-specific CD28 deficiency promoted a broader inflammatory microglial state together with increased amyloid plaque burden.”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourceSupported

Classified as probably not a substantial claim. May combine two claims.

CD80 and CD86 are traditionally expressed by antigen-presenting cells and bind CD28 and CTLA-4 on T cells.

“CD80 and CD86 are traditionally expressed by antigen-presenting cells and bind CD28 and CTLA-4 on T cells.”

• cites [40] Bugeon, 2000, Costimulation of T cells, Am. J. Respir. Crit. Care Med. sourceNot checked — no full text of the source
• cites [42] Lanier, 1995, CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL, J. Immunol. sourceNot checked — no full text of the source
• cites [45] Almolda, 2015, Are Microglial Cells the Regulators of Lymphocyte Responses in the CNS?, Front. Cell Neurosci. sourceSupported

Classified as probably not a substantial claim. May combine two claims.

CD28 and B7-family pathways are deeply involved in peripheral immune regulation, so systemic manipulation could affect T-cell responses, autoimmunity, infection risk, or immunosurveillance.

“CD28 and B7-family pathways are deeply involved in peripheral immune regulation, so systemic manipulation could affect T-cell responses, autoimmunity, infection risk, or immunosurveillance.”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourcePartly supported

  The Main section describes CD28 as a well-known T-cell co-stimulatory protein, supporting its role in immune regulation. But the paper focuses on microglia in Alzheimer’s disease; it does not address systemic manipulation of CD28 or B7-family pathways or the proposed effects on autoimmunity, infection risk, or immunosurveillance. Page numbers are unavailable in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [48] McGeer, 2007, NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies, Neurobiol. Aging sourceNot checked — no full text of the source

May combine two claims.

In mouse models, clonally expanded CD8-positive T cells interact dynamically with microglia: early CD8-positive T-cell activity can worsen amyloid pathology and constrain DAM-like microglial transition, whereas later T-cell states may become more tissue-resident or regulatory.

“In mouse models, clonally expanded CD8-positive T cells have also been shown to interact dynamically with microglia: early CD8-positive T-cell activity can worsen amyloid pathology and constrain DAM-like microglial transition, whereas later T-cell states may become more tissue-resident or regulatory.”

• cites [37] Rickenbach, 2025, Altered T-cell reactivity in the early stages of Alzheimer’s disease, Brain sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [39] Ohyagi, 2025, Stage-specific roles of clonally expanded CD8+ T cells in regulating amyloid pathology in Alzheimer’s disease models, Nat. Commun. sourceSupported

Classified as probably not a substantial claim. May combine two claims.

In Alzheimer's disease and aging, microglia and peripheral myeloid cells may express co-stimulatory ligands, but the ligand-receptor architecture within the plaque microenvironment remains incompletely defined.

“In Alzheimer’s disease and aging, microglia and peripheral myeloid cells may express co-stimulatory ligands, but the ligand–receptor architecture within the plaque microenvironment remains incompletely defined.”

• cites [40] Bugeon, 2000, Costimulation of T cells, Am. J. Respir. Crit. Care Med. sourceNot checked — no full text of the source
• cites [42] Lanier, 1995, CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL, J. Immunol. sourceNot checked — no full text of the source
• cites [45] Almolda, 2015, Are Microglial Cells the Regulators of Lymphocyte Responses in the CNS?, Front. Cell Neurosci. sourcePartly supported

  The section “Expression of Co-stimulatory Molecules in Microglia” (page unavailable) reports microglial CD40 expression in aging and Alzheimer’s disease and identifies gaps in knowledge about other co-stimulatory molecules. It does not establish co-stimulatory ligand expression by peripheral myeloid cells or specifically assess ligand–receptor relationships within the plaque microenvironment. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Microglia can compact plaques, clear amyloid-β, remove debris, regulate lipid stress, support repair, and coordinate local tissue responses, even while they can also produce cytokines, engage complement-mediated synapse loss, and contribute to chronic inflammatory injury.

“Microglia can compact plaques, clear amyloid-β, remove debris, regulate lipid stress, support repair, and coordinate local tissue responses, even while they can also produce cytokines, engage complement-mediated synapse loss, and contribute to chronic inflammatory injury.”

• cites [50] AmeliMojarad, 2024, The neuroinflammatory role of microglia in Alzheimer’s disease and their associated therapeutic targets, CNS Neurosci. Ther. sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [51] Houchois, 2024, The Challenges of Modulating Neuroinflammation in Alzheimer’s Disease and Multiple Sclerosis with TREM2 Agonistic Antibodies, J. Neurosci. sourceNot checked — no full text of the source

May combine two claims.

Anti-amyloid antibodies can reduce amyloid burden, but clinical benefit has remained modest and safety concerns such as amyloid-related imaging abnormalities have limited enthusiasm in some health systems.

“Anti-amyloid antibodies can reduce amyloid burden, but clinical benefit has remained modest and safety concerns such as amyloid-related imaging abnormalities have limited enthusiasm in some health systems.”

• cites [54] Nonino, 2026, Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, Cochrane Database Syst. Rev. sourcePartly supported

  The Background reports reduced brain amyloid, and the Authors’ conclusions describe clinical effects as small or absent and ARIA risk as high. The paper also discusses healthcare-system burdens and debate over net benefit, but it does not establish that safety concerns have limited enthusiasm in particular health systems. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Pathways that support amyloid plaque response may have different consequences in tau-rich or late-stage disease.

“pathways that support amyloid plaque response may have different consequences in tau-rich or late-stage disease [55,60]”

• cites [55] Huang, W., Huang, J., Huang, N., and Luo, Y. (2023). The role of TREM2 in Alzheimer’s disease: From the perspective of Tau. Front. Cell Dev. Biol., 11. sourceSupported
• cites [60] Abdulkhaliq, 2026, TREM2 in neurodegeneration and diseases, Mol. Psychiatry sourcePartly supported

  The section on TREM2 in Alzheimer’s-associated neuroinflammation says TREM2 can support amyloid-β responses yet may have different effects when tau pathology occurs, supporting the tau-related part of the claim. It does not establish the same distinction specifically for late-stage disease; its stage-specific discussion concerns early- and middle-stage models. No page numbers are available in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S2 (checkable).

The challenge is not simply to reduce inflammation, but to modulate it with enough precision to preserve protective microglial activity while preventing maladaptive activation.

“Recent reviews of neuroinflammation therefore emphasize that the challenge is not simply to reduce inflammation, but to modulate it with enough precision to preserve protective microglial activity while preventing maladaptive activation [50,51].”

• cites [50] AmeliMojarad, 2024, The neuroinflammatory role of microglia in Alzheimer’s disease and their associated therapeutic targets, CNS Neurosci. Ther. sourceSupported
• cites [51] Houchois, 2024, The Challenges of Modulating Neuroinflammation in Alzheimer’s Disease and Multiple Sclerosis with TREM2 Agonistic Antibodies, J. Neurosci. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

TREM2 is a microglial receptor involved in lipid sensing, survival, phagocytosis, metabolism, and plaque-associated microglial responses.

“The best-developed example is TREM2, a microglial receptor involved in lipid sensing, survival, phagocytosis, metabolism, and plaque-associated microglial responses.”

• cites [52] Feiten, 2026, TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism, Nat. Commun. sourcePartly supported

  The Introduction identifies TREM2 as predominantly expressed in microglia and links it to phagocytosis, metabolism, and clustering around amyloid plaques. The Discussion also links TREM2 to microglial survival under stress and lipid metabolism. Lipid sensing appears in a cited work’s title in the References, but the paper’s substantive passages do not describe that receptor function; that part of the claim is not established by our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [53] Wang, T., Liu, X., Wang, X., Hua, F., and Yan, L. (2026). TREM2 and microglial immunity in Alzheimer’s disease: Mechanisms, genetics, and therapeutic opportunities. Front. Immunol., 17. sourceSupported

May combine two claims.

In several transgenic mouse models representing amyloid deposition, tauopathy, and neurodegeneration, A11 reduced neuroinflammation and neuropathology and improved cognitive performance.

“In several transgenic mouse models representing different Alzheimer’s disease-related pathological features, including amyloid deposition, tauopathy, and neurodegeneration, A11 reduced neuroinflammation and neuropathology and improved cognitive performance [38].”

• cites [38] Ralvenius, 2023, A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation, J. Exp. Med. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Microglia may interact with oligodendrocyte-lineage cells in disease-specific ways, as suggested by newer single-nucleus studies across dementia subtypes.

“newer single-nucleus studies across dementia subtypes suggest that microglia may also interact with oligodendrocyte-lineage cells in disease-specific ways [58,61]”

• cites [58] Mallach, 2024, Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer’s disease mouse model, as revealed by spatial transcriptomics, Cell Rep. sourceCould not verify

  The ‘Cellular effects within the plaque niche’ section reports that microglia and oligodendrocytes are both present in amyloid-plaque niches, but does not establish an interaction between them. The paper examines spatial transcriptomics in an Alzheimer’s mouse model; the passages found do not address single-nucleus studies across dementia subtypes or disease-specific microglia–oligodendrocyte interactions (searched: oligodendrocyte interactions and single-nucleus dementia subtypes). (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [61] Chia, 2025, Single-nucleus transcriptomics reveals a distinct microglial state and increased MSR1-mediated phagocytosis as common features across dementia subtypes, Genome Med. sourceSupported

May combine two claims.

A11 had no major effects on hematopoietic stem-cell proliferation or differentiation at tested concentrations and no major changes in circulating CD45-positive, CD4-positive, or CD8-positive cells after repeated treatment in mice.

“The authors also reported no major effects on hematopoietic stem-cell proliferation or differentiation at tested concentrations and no major changes in circulating CD45-positive, CD4-positive, or CD8-positive cells after repeated treatment in mice.”

• cites [38] Ralvenius, 2023, A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation, J. Exp. Med. sourceSupported

May combine two claims.

Human spatial studies have identified plaque-glia niches and altered co-expression patterns around amyloid deposits.

“Human spatial studies have already begun to identify plaque-glia niches and altered co-expression patterns around amyloid deposits”

• cites [59] Avey, D.R., Ng, B., Vialle, R.A., Kearns, N.A., de Paiva Lopes, K., Iatrou, A., De Tissera, S., Vyas, H., Saunders, D.M., and Flood, D.J. (2024). Uncovering Plaque-Glia Niches in Human Alzheimer’s Disease Brains Using Spatial Transcriptomics. bioRxiv. sourceSupported

Classified as probably not a substantial claim. May combine two claims.

In peripheral immunology, CD28 is a central T-cell co-stimulatory receptor, and interventions affecting CD28 or its B7-family ligand network can have major consequences for immune activation, tolerance, autoimmunity, and infection risk.

“In peripheral immunology, CD28 is a central T-cell co-stimulatory receptor, and interventions affecting CD28 or its B7-family ligand network can have major consequences for immune activation, tolerance, autoimmunity, and infection risk.”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourcePartly supported

  The Main section (page not provided) describes CD28 as a well-known T-cell co-stimulatory signalling protein, supporting the first part of the claim. Its reported CD28 intervention concerns microglia in Alzheimer’s disease mice; the passages do not address peripheral interventions involving CD28 or B7-family ligands, or their consequences for tolerance, autoimmunity, or infection risk. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [48] McGeer, 2007, NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies, Neurobiol. Aging sourceNot checked — no full text of the source

May combine two claims.

Spi1 knockdown aggravated amyloid aggregation, plaque accumulation, and gliosis in a 2024 study.

“A 2024 study reported that Spi1 knockdown aggravated amyloid aggregation, plaque accumulation, and gliosis”

• cites [36] Kim, 2024, Effects of SPI1-mediated transcriptome remodeling on Alzheimer’s disease-related phenotypes in mouse models of Aβ amyloidosis, Nat. Commun. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Spatial transcriptomic studies of plaque niches have highlighted microglia-astrocyte crosstalk around amyloid deposits.

“Spatial transcriptomic studies of plaque niches have highlighted microglia–astrocyte crosstalk around amyloid deposits”

• cites [58] Mallach, 2024, Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer’s disease mouse model, as revealed by spatial transcriptomics, Cell Rep. sourceSupported
• cites [61] Chia, 2025, Single-nucleus transcriptomics reveals a distinct microglial state and increased MSR1-mediated phagocytosis as common features across dementia subtypes, Genome Med. sourceCould not verify

  The Results section, “Identification of a distinct state of microglia across dementia subtypes” (page unavailable), describes potential microglia–oligodendrocyte interactions assessed with RNAscope. Searches for spatial transcriptomics, astrocytes, and amyloid plaque niches found no passage in our copy reporting microglia–astrocyte crosstalk around deposits. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

TREM2-related microglial activation may support amyloid plaque engagement.

“TREM2-related microglial activation may support amyloid plaque engagement”

• cites [55] Huang, W., Huang, J., Huang, N., and Luo, Y. (2023). The role of TREM2 in Alzheimer’s disease: From the perspective of Tau. Front. Cell Dev. Biol., 11. sourceSupported
• cites [56] Carling, 2023, Friend turned foe: TREM2 agonist in battles against tau, J. Exp. Med. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

The role of TREM2-related microglial activation in tau-dominant or later-stage disease is more controversial.

“its role in tau-dominant or later-stage disease is more controversial”

• cites [55] Huang, W., Huang, J., Huang, N., and Luo, Y. (2023). The role of TREM2 in Alzheimer’s disease: From the perspective of Tau. Front. Cell Dev. Biol., 11. sourceSupported
• cites [56] Carling, 2023, Friend turned foe: TREM2 agonist in battles against tau, J. Exp. Med. sourceSupported

Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing). May combine two claims.

These findings remain preclinical and should be interpreted cautiously.

“Nevertheless, these findings remain preclinical and should be interpreted cautiously [38].”

• cites [38] Ralvenius, 2023, A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation, J. Exp. Med. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

PU.1-low CD28-expressing microglia can reduce neuroinflammation and amyloid pathology, as reported by Ayata et al.

“Ayata et al. reported that PU.1-low CD28-expressing microglia can reduce neuroinflammation and amyloid pathology”

• cites [20] Ayata, 2025, Lymphoid gene expression supports neuroprotective microglia function, Nature sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Enhancing TREM2 signaling may strengthen the ability of microglia to respond to amyloid plaques and neuronal damage.

“TREM2 has attracted therapeutic interest because enhancing TREM2 signaling may strengthen the ability of microglia to respond to amyloid plaques and neuronal damage.”

• cites [52] Feiten, 2026, TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism, Nat. Commun. sourceSupported
• cites [53] Wang, T., Liu, X., Wang, X., Hua, F., and Yan, L. (2026). TREM2 and microglial immunity in Alzheimer’s disease: Mechanisms, genetics, and therapeutic opportunities. Front. Immunol., 17. sourceSupported

Classified as probably not a substantial claim.

The question of whether SPI1 should be increased or decreased for therapeutic benefit remains unresolved.

“The fact that this question remains unresolved is important.”

May combine two claims.

High or sustained PU.1 activity may support myeloid identity and certain inflammatory or phagocytic programs, whereas partial reduction may permit alternative transcriptional states, including disease-associated or lymphoid-like suppressive programs.

“High or sustained PU.1 activity may support myeloid identity and certain inflammatory or phagocytic programs, whereas partial reduction may permit alternative transcriptional states, including disease-associated or lymphoid-like suppressive programs.”

Probably not a substantial claim: may not pass S2 (checkable).

The most plausible therapeutic interpretation is that PU.1 dosage may need to be tuned to favor protective microglial states while avoiding loss of core microglial function, rather than globally suppressed.

“Therefore, the most plausible therapeutic interpretation is not that PU.1 should be globally suppressed, but that PU.1 dosage may need to be tuned to favor protective microglial states while avoiding loss of core microglial function.”

• AssumptionRests on an assumption: Human genetics indicates that lower SPI1 expression can be protective.
• AssumptionRests on an assumption: PU.1 is required for essential myeloid identity and disease-response functions.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

A PU.1-low microglial cell could be protective, exhausted, developmentally unstable, or functionally impaired depending on context.

“A PU.1-low microglial cell could be protective, exhausted, developmentally unstable, or functionally impaired depending on context.”

May combine two claims.

PU.1 may help determine not only whether microglia activate, but also what kind of activation state they adopt.

“PU.1 may therefore help determine not only whether microglia activate, but also what kind of activation state they adopt.”

• AssumptionRests on an assumption: TREM2 is central to plaque-associated microglial responses, lipid handling, and disease-associated microglial states.

Probably not a substantial claim: may not pass S2 (checkable).

Alzheimer's immunotherapy may require state-specific microglial modulation rather than simple activation or inhibition.

“This would fit with the emerging view that Alzheimer’s immunotherapy may require state-specific microglial modulation rather than simple activation or inhibition.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

CD28 is a co-stimulatory receptor on T cells; engagement by CD80 and CD86 on antigen-presenting cells provides a second signal supporting T-cell activation, survival, proliferation, cytokine production, and differentiation.

“In classical immunology, CD28 is best known as a co-stimulatory receptor on T cells. Its engagement by the B7-family ligands CD80 and CD86 on antigen-presenting cells provides a second signal that supports T-cell activation, survival, proliferation, cytokine production, and differentiation.”

• cites [40] Bugeon, 2000, Costimulation of T cells, Am. J. Respir. Crit. Care Med. sourceNot checked — no full text of the source
• cites [41] Porciello, 2016, CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling, Cytokine Growth Factor Rev. sourceNot checked — no full text of the source
• cites [42] Lanier, 1995, CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL, J. Immunol. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Without CD28 co-stimulation, antigen recognition alone may lead to incomplete activation, tolerance, or anergy.

“Without this co-stimulatory context, antigen recognition alone may lead to incomplete activation, tolerance, or anergy.”

• cites [40] Bugeon, 2000, Costimulation of T cells, Am. J. Respir. Crit. Care Med. sourceNot checked — no full text of the source
• cites [41] Porciello, 2016, CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling, Cytokine Growth Factor Rev. sourceNot checked — no full text of the source
• cites [42] Lanier, 1995, CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL, J. Immunol. sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

The same molecular module can have different consequences depending on cell type, receptor context, ligand availability, transcriptional state, and tissue environment.

“This does not necessarily contradict classical immunology; rather, it shows that the same molecular module can have different consequences depending on the cell type, receptor context, ligand availability, transcriptional state, and tissue environment.”

Probably not a substantial claim: may not pass S2 (checkable), S4 (based). May combine two claims.

If CD28-positive suppressive microglia are protective, the therapeutic goal would be to preserve or expand a regulatory state that restrains damaging inflammation while maintaining plaque containment and debris clearance, not to suppress microglia globally.

“If CD28-positive suppressive microglia are protective, then the goal would not be to suppress microglia globally, but to preserve or expand a regulatory state that restrains damaging inflammation while maintaining plaque containment and debris clearance.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

CD80 and CD86 are potent T-cell co-stimulators, and CD28 tunes the quality, duration, and metabolic consequences of immune activation.

“Early studies in the 1990s established CD80 and CD86 as potent T-cell co-stimulators, while later reviews refined the view of CD28 as a receptor that does not simply “turn on” T cells, but tunes the quality, duration, and metabolic consequences of immune activation [40,41,42].”

• cites [40] Bugeon, 2000, Costimulation of T cells, Am. J. Respir. Crit. Care Med. sourceNot checked — no full text of the source
• cites [41] Porciello, 2016, CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling, Cytokine Growth Factor Rev. sourceNot checked — no full text of the source
• cites [42] Lanier, 1995, CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL, J. Immunol. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S2 (checkable).

CD28 should be interpreted as part of a broader regulatory module whose function must be defined in microglia, not inferred directly from T-cell co-stimulation.

“The key implication is that CD28 should be interpreted as part of a broader regulatory module whose function must be defined in microglia, not inferred directly from T-cell co-stimulation.”

Probably not a substantial claim: may not pass S2 (checkable).

The attractive therapeutic idea is not to silence microglia, but to increase the probability that disease-exposed microglia adopt a regulatory, plaque-protective, inflammation-limiting state.

“The attractive therapeutic idea is therefore not to silence microglia, but to increase the probability that disease-exposed microglia adopt a regulatory, plaque-protective, inflammation-limiting state.”

Probably not a substantial claim: may not pass S2 (checkable).

A more plausible therapeutic model is partial, contextual, or cell-state-specific modulation of PU.1-regulated programs.

“A more plausible therapeutic model is therefore partial, contextual, or cell-state-specific modulation of PU.1-regulated programs.”

Probably not a substantial claim: may not pass S2 (checkable).

Treating too late might be insufficient if neuronal loss, tau spread, and glial dysfunction have become self-sustaining.

“Treating too late might be insufficient if neuronal loss, tau spread, and glial dysfunction have become self-sustaining.”

May combine two claims.

PU.1-associated transcriptional programs are pharmacologically tractable and may be modulated in a more state-selective manner than older broad anti-inflammatory approaches.

“The key implication for the present review is not that A11 is already a clinically validated Alzheimer’s therapy, but that PU.1-associated transcriptional programs are pharmacologically tractable and may be modulated in a more state-selective manner than older broad anti-inflammatory approaches.”

May combine two claims.

PU.1 is a core myeloid transcription factor, and excessive or poorly timed suppression may damage microglial functions needed for amyloid response and tissue maintenance.

“It is a core myeloid transcription factor, and excessive or poorly timed suppression may damage the very microglial functions needed for amyloid response and tissue maintenance.”

• AssumptionRests on an assumption: PU.1 is required for essential myeloid identity and disease-response functions.

May combine two claims.

If some microglial responses are protective while others are damaging, global microglial inhibition may remove beneficial functions along with harmful ones.

“If some microglial responses are protective while others are damaging, then global microglial inhibition may remove beneficial functions along with harmful ones.”

Probably not a substantial claim: may not pass S2 (checkable).

Microglial state modulation could become relevant as an adjunct strategy that improves the brain's inflammatory and clearance response to amyloid- or tau-directed interventions.

“Microglial state modulation could become relevant as an adjunct strategy that improves the brain’s inflammatory and clearance response to amyloid- or tau-directed interventions.”

Probably not a substantial claim: may not pass S2 (checkable).

Suppressive microglia may be most useful when combined conceptually with amyloid- or tau-directed therapies.

“Another implication is that suppressive microglia may be most useful when combined conceptually with amyloid- or tau-directed therapies.”

May combine two claims.

A11 dampens PU.1-dependent inflammatory activity while avoiding complete disruption of PU.1 expression, which is essential for myeloid identity and hematopoiesis.

“A11 represents an example of how PU.1-dependent inflammatory activity might be dampened while avoiding complete disruption of PU.1 expression, which is essential for myeloid identity and hematopoiesis.”

• AssumptionRests on an assumption: PU.1 is required for essential myeloid identity and disease-response functions.

Classified as probably not a substantial claim.

Lymphoid-like suppressive microglia remain a promising but still incompletely validated concept.

“At present, lymphoid-like suppressive microglia remain a promising but still incompletely validated concept.”